Table 1.
The relationship between the expression of NTN4 and clinicopathological data.
| Characteristic | NTN4 mRNA | P | |
|---|---|---|---|
| Low(n = 541) | High(n = 542) | ||
| Age (years) | 0.035 | ||
| Median (IQR) | 57 (48, 66) | 60 (49, 68) | 0.012 |
| < = 60 | 318 (29.4%) | 283 (26.1%) | |
| > 60 | 223 (20.6%) | 259 (23.9%) | |
| T stage, n (%) | < 0.001 | ||
| T1 | 113 (10.5%) | 164 (15.2%) | |
| T2 | 349 (32.3%) | 280 (25.9%) | |
| T3 | 60 (5.6%) | 79 (7.3%) | |
| T4 | 17 (1.6%) | 18 (1.7%) | |
| N stage, n (%) | 0.653 | ||
| N0 | 258 (24.2%) | 256 (24.1%) | |
| N1 | 179 (16.8%) | 179 (16.8%) | |
| N2 | 61 (5.7%) | 55 (5.2%) | |
| N3 | 33 (3.1%) | 43 (4%) | |
| M stage, n (%) | 1.000 | ||
| M0 | 452 (49%) | 450 (48.8%) | |
| M1 | 10 (1.1%) | 10 (1.1%) | |
| Menopause status, n (%) | 0.916 | ||
| Pre | 117 (12%) | 112 (11.5%) | |
| Peri | 20 (2.1%) | 20 (2.1%) | |
| Post | 348 (35.8%) | 355 (36.5%) | |
| Histological type, n (%) | < 0.001 | ||
| Infiltrating Ductal Carcinoma | 440 (45%) | 332 (34%) | |
| Infiltrating Lobular Carcinoma | 52 (5.3%) | 153 (15.7%) | |
| Pathologic stage, n (%) | 0.004 | ||
| Stage I | 71 (6.7%) | 110 (10.4%) | |
| Stage II | 335 (31.6%) | 284 (26.8%) | |
| Stage III | 117 (11%) | 125 (11.8%) | |
| Stage IV | 8 (0.8%) | 10 (0.9%) | |
| PR status, n (%) | < 0.001 | ||
| Negative | 267 (25.8%) | 75 (7.3%) | |
| Indeterminate | 3 (0.3%) | 1 (0.1%) | |
| Positive | 245 (23.7%) | 443 (42.8%) | |
| ER status, n (%) | < 0.001 | ||
| Negative | 202 (19.5%) | 38 (3.7%) | |
| Indeterminate | 1 (0.1%) | 1 (0.1%) | |
| Positive | 313 (30.2%) | 480 (46.4%) | |
| HER2 status, n (%) | 0.438 | ||
| Negative | 264 (36.3%) | 294 (40.4%) | |
| Indeterminate | 7 (1%) | 5 (0.7%) | |
| Positive | 82 (11.3%) | 75 (10.3%) | |
IQR interquartile range.